Valneva shares rebound but are down 15.5% over three months
The Lyon-based vaccine company is recovering markedly at midday, while the Paris stock market is posting a modest gain. This rebound follows several sessions of decline and comes a few days before the publication of its accounts.
A rebound that leaves the stock below its moving averages
Valneva shares gain 2.43% to €2.49 during the session, ranking among the strongest gains in its index, while the SBF 120 rises 0.35%. The stock nonetheless remains 1.15% below its MM20 (€2.52), and both the MM50 and the MM200 are also above the share price.
The move recovers only part of the week's decline, which reaches 6.95% over seven days, following a Wednesday session spent in the bottom of the index. The RSI at 47 remains neutral. The support at €2.33 is the nearest downside level, while the resistance at €2.68 is the nearest upside level.
Results for the first nine months expected on November 24
Valneva will publish its results for the first nine months of 2026 on November 24. When it published its H1 2026 results on August 13, the company confirmed its outlook for the year despite the persistent negative impact of the geopolitical context on travel.
Among the risks cited on that occasion was the company's dependence on IXIARO deliveries to the U.S. Department of Defense, whose timing remains uncertain.
On the clinical front, the group released new data in early November on its chikungunya vaccine, with a seroresponse maintained at 94% five years after a single dose. Over three months, the stock has fallen 15.47%. The November 24 publication is the company's next scheduled event.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorPharmacie et biotechnologies›Pharmacie, vaccins et santé animale
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
EBITDA margin: -60,4 %
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.